Aarti Drugs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Aarti Drugs Ltd reported a 19.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.3%.
• Its expenses for the quarter were up by 13.4% QoQ and 7.1% YoY.
• The net profit increased 36.3% QoQ and decreased 12.0% YoY.
• The earnings per share (EPS) of Aarti Drugs Ltd stood at 6.05 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Drugs Ltd is a pharmaceutical company primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company operates within the broader pharmaceutical and healthcare industry, which is characterized by its focus on developing and producing medications to treat various diseases and conditions. Aarti Drugs Ltd has been a notable player in this industry, contributing to the production of essential drugs and chemicals that support healthcare systems both domestically and internationally. Recent major developments within the company are not available from the provided data.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Aarti Drugs Ltd reported a total income of ₹721.06 crores. This represents a quarter-over-quarter (QoQ) increase of 19.6% from the previous quarter (Q3FY26), where the total income was ₹602.94 crores. Additionally, there was a year-over-year (YoY) increase of 6.3% compared to the fourth quarter of the previous fiscal year (Q4FY25), where the total income stood at ₹678.63 crores. These figures indicate the company's revenue performance over the quarterly and yearly periods.

Profitability

The company's profitability metrics for Q4FY26 include a profit before tax of ₹70.36 crores, reflecting a substantial QoQ increase of 142.4% from Q3FY26, where the profit before tax was ₹29.03 crores. Compared to Q4FY25, however, there was a slight YoY decrease of 1.1%, as the profit before tax during that period was ₹71.15 crores. The profit after tax (PAT) for Q4FY26 was ₹55.26 crores, which is a 36.3% increase QoQ from ₹40.55 crores in Q3FY26, though it decreased by 12.0% YoY from ₹62.77 crores in Q4FY25. Earnings per share (EPS) followed a similar pattern, increasing by 36.3% QoQ to ₹6.05 but decreasing by 12.1% YoY compared to ₹6.88 in Q4FY25.

Operating Metrics

Total expenses for Aarti Drugs Ltd in Q4FY26 amounted to ₹650.70 crores, marking a 13.4% increase QoQ from ₹573.91 crores in Q3FY26. On a YoY basis, expenses rose by 7.1% compared to ₹607.48 crores in Q4FY25. The tax expense for Q4FY26 was ₹15.10 crores, which saw a dramatic change from the previous quarter's negative tax figure of -₹11.52 crores, reflecting a significant QoQ shift. YoY, the tax expense increased by 80.2% from ₹8.38 crores in Q4FY25. These operating metrics provide insights into the company's cost structure and tax obligations over the reported periods.